Table 3.
The primary end point results in the 18 months observational periods after 6 months inhaled GM-CSF treatment
| 9 months | 12 months | 18 months | 24 months | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control group (n = 12) | Treatment group (n = 14) | P value | Control group (n = 13) | Treatment group (n = 14) | P value | Control group (n = 12) | Treatment group (n = 13) | P value | Control group (n = 11) | Treatment group (n = 15) | P value | |
| Δ A-aDO2 (mmHg) | 4.53 ± 7.59 | 8.11 ± 10.89 | 0.461 | 5.19 ± 9.72 | 7.02 ± 12.35 | 0.674 | 8.13 ± 15.02 | 7.39 ± 8.677 | 0.579 | 6.05 ± 11.14 | 6.61 ± 10.64 | 0.899 |
| A-aDO2 (mmHg) | 25.24 ± 7.05 | 22.16 ± 9.09 | 0.366 | 22.35 ± 6.54 | 23.25 ± 8.10 | 0.756 | 18.38 ± 10.50 | 22.24 ± 9.43 | 0.343 | 23.72 ± 9.41 | 23.66 ± 8.96 | 0.988 |
| Δ PaO2 (mmHg) | 4.29 ± 8.38 | 7.45 ± 11.82 | 0.267 | 2.78 ± 11.41 | 5.89 ± 11.91 | 0.496 | 8.13 ± 15.02 | 7.71 ± 8.72 | 0.931 | 6.16 ± 9.88 | 4.76 ± 10.72 | 0.741 |
| PaO2 (mmHg) | 81.08 ± 7.14 | 84.15 ± 8.93 | 0.362 |
81.84 ±7.13 |
82.59 ± 7.70 | 0.794 | 86.48 ± 10.75 | 84.99 ± 9.76 | 0.721 | 82.95 ± 8.05 | 81.46 ± 10.84 | 0.707 |
Abbreviations: see Table 1